Univariate and multivariate analysis for overall survival (OS) in 252 patients
| Patients | No of patients n=252 | No of event n=51 | Median OS | 95% CI | Actuarial 5 years OS (%) | Univariate analysis | Multivariate analysis | ||
| HR (95% CI) | P value | HR (95% CI) | P value | ||||||
| Gender | |||||||||
| Female | 130 | 24 | 62.2 | 14.9 to 109.5 | 89.7 | 1 | 0.441 | 1 | 0.306 |
| Male | 122 | 27 | 50.6 | 3.0 to 98.2 | 86.1 | 0.803 (0.459 to 1.403) | 0.709 (0.367 to 1.369) | ||
| Age, years | |||||||||
| ˂60 | 156 | 30 | 69.2 | 48.8 to 89.6 | 87.5 | 1 | 0.038 | 1 | 0.856 |
| ≥60 | 96 | 21 | 23.8 | 6.0 to 41.6 | 82.0 | 1.854 (1.035 to 3.320) | 1.084 (0.455 to 2.581) | ||
| Presence of B symptoms | |||||||||
| No | 183 | 27 | 79.5 | 58.8 to 100.2 | 89.6 | 1 | 0.001 | 1 | 0.035 |
| Yes | 69 | 24 | 18.1 | 0.0 to 41.3 | 71.3 | 0.354 (0.192 to 0.651) | 0.392 (0.164 to 0.936) | ||
| Tumor sites | |||||||||
| Proximal or ≥2 components | 39 | 5 | 98.2 | 0.0 to 280.5 | 88.7 | 1 | 0.488 | – | |
| Distal | 213 | 46 | 55.7 | 24.0 to 87.4 | 86.9 | 1.392 (0.546 to 3.552) | – | ||
| Lugano stage | |||||||||
| IE | 150 | 24 | 69.2 | 41.6 to 96.8 | 89.8 | 1 | 0.046 | 1 | 0.381 |
| IIE | 102 | 27 | 40.2 | 5.6 to 74.8 | 80.3 | 1.823 (1.011 to 3.288) | 1.502 (0.605 to 3.792) | ||
| IPI risk group | |||||||||
| Low (intermediate) risk | 124 | 29 | 79.5 | 73.9 to 85.1 | 91.7 | 1 | 0.000 | 1 | 0.379 |
| High risk or relapse | 128 | 22 | 16.3 | 6.4 to 26.2 | 84.9 | 4.030 (2.125 to 7.645) | 0.521 (0.122 to 2.227) | ||
| ECOG | |||||||||
| 0–1 | 214 | 38 | 56.5 | 29.3 to 83.7 | 90.0 | 1 | 0.023 | 1 | 0.043 |
| ≥2 | 38 | 13 | 9.7 | 0.0 to 68.5 | 76.8 | 2.155 (1.111 to 4.180) | 3.137 (1.038 to 9.482) | ||
| Histological analyses | |||||||||
| Non-GCB | 173 | 34 | 30.2 | 0.0 to 84.8 | 88.1 | 1 | 0.215 | – | |
| GCB | 79 | 17 | 68.6 | 50.4 to 86.8 | 87.8 | 1.472 (0.799 to 2.713) | – | ||
| Lactate dehydrogenase | |||||||||
| ˂200 U/L | 182 | 33 | 79.5 | 60.4 to 98.6 | 86.3 | 1 | 0.000 | 1 | 0.000 |
| ≥200 U/L | 70 | 18 | 8.7 | 0.0 to 20.3 | 74.0 | 27.757 (7.652 to 100.685) | 45.390 (9.376 to 219.741) | ||
| Helicobacter pylori with therapeutic response and TIL-Ts status | |||||||||
| Others | 143 | 40 | 28.1 | 4.9 to 51.3 | 76.6 | 1 | 0.000 | 1 | 0.000 |
| H. pylori-positive with pCR and high TIL-Ts | 109 | 11 | 138.9 | 111.8 to 166.0 | 89.2 | 18.132 (5.199 to 63.245) | 26.305 (5.410 to 127.901) | ||
The p values with statistical significance are shown in bold.
Proximal: middle body, upper body, fundus or cardia; Distal: antrum, angle or lower body.
ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell; IPI, International Prognostic Index; pCR, complete pathological remission; TIL-Ts, tumor-infiltrating T-lymphocytes.